MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Inclusion Criteria: * Adult participants; age ≥ 18 * Written and signed informed consent must be obtained * Have histologic or cytologic documentation of solid tumor including EGFRm NSCLC * Participants must have at least 1 lesion that is measurable using RECIST guidelines * Participants must consent to provide archived tumor specimens or tumor biopsies for correlative biomarker studies. * Eastern Cooperative Oncology Group performance score of 0 or 1 * Adequate organ function Exclusion Criteria: * Prior treatment with tumor necrosis factor receptor superfamily agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, PD-L1, and anti PD-L1. * Participants who have received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists may be permitted to enroll under certain conditions * Cardiac or peripheral vascular disease meeting any of the following criteria: * Past history of myocardial infarction in the prior 12 months * Past history of stroke or transient ischemic attack requiring medical therapy * Congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification * Grade 3 or greater edema (eg, peripheral, pulmonary) * History of Grade 3 or greater thromboembolic events in the prior 12 months * Participants with active tuberculosis are ineligible. In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be ruled out * Active or prior doc…